Evidence map›Paper›PMID 38389928›Full record

ArticleFrontiers in pharmacology2024

Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.

Lili Shang, Yan Cheng, Jifang Zhou, Yuqing Bao, Desong Kong, Ruijian Huang, Yanfei Chen, Hao Wang, Ning Gu, Aixia Ma

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lili Shang *School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Yan Cheng *Department of Pharmacy, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Jifang ZhouSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Yuqing BaoSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Desong KongChinese Medicine Modernization and Big Data Research Center, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Ruijian HuangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Yanfei ChenSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Hao WangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Ning Gu *Cardiovascular Department, Nanjing Hospital of Chinese Medicine, Nanjing, China.
Aixia MaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antihypertensive drugshealthcare expendituresinterrupted time seriesnational centralized drug procurementnational volume-based drug procurementvolume-based procurement antihypertensive drugs

Identifiers

PMID38389928
PMCPMC10881800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.